Artoss, Inc. Announces FDA Clearance of NanoBone® SBX Putty

for Standalone Use in Posterolateral Spinal Fusion


Press Release April 24, 2019

Artoss, Inc. is pleased to announce that the US Food & Drug Administration has cleared NanoBone SBX Putty for standalone use in posterolateral spinal fusion. NanoBone was tested alone (without addition of autograft or bone marrow aspirate) in the ASTM International standardized animal model and found to be equivalent to the “gold standard” autograft in fusion rate.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “The ASTM standard animal model for lumbar intertransverse process spinal fusion is a very challenging model designed to replicate clinically relevant fusion rates for iliac crest autograft in the posterolateral spine. A majority of bone void fillers must be mixed with autograft in order to achieve equivalent fusion rates to autograft alone. We’re pleased to offer surgeons a synthetic alternative to autograft that does not require mixing with autograft or bone marrow. Using a synthetic bone void filler alone offers significant cost savings to hospitals. NanoBone stands alone.”

“NanoBone Bone Graft used as a standalone in posterolateral spinal fusion represents a significant advancement in patient care.” said J. Eric Gee, M.D. “Eliminating the need to mix synthetic graft with autograft or to harvest and concentrate bone marrow aspirate will save time and money as well as streamline operating room procedures.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
425 E Saint Germain St., Suite 106
Saint Cloud, MN 56304
320-259-4321
info@artossinc.com

 

Artoss, Inc. Announces Hiring of Gabriel "Gabe" Ortiz as Director of Sales, Western Region


Press Release March 28, 2019

Artoss, Inc. is pleased to announce the hiring of Gabe Ortiz as Director of Sales, Western Region. In this role, Gabe will be responsible for continuing the sales growth of NanoBone® Bone Graft in a thirteen–state region west of the Mississippi River and for identifying, training, and managing independent distributors in that region.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Gabe has a wealth of experience in building and managing orthobiologic sales organizations. He had nationwide responsibilities as Vice President of Sales for Prosidyan. Prior to that, he spent ten years with Medtronic building and leading the Biologics Organization in the West with sales of Infuse® Bone Graft and the complete allograft/synthetic product portfolio. We’re pleased that Gabe recognizes the opportunity to represent the best standalone synthetic graft on the market and welcome him to Artoss.”

“I am very excited to join the well-established and respected executive team of Paul Byerley and Jim Cassidy to continue to drive the tremendous momentum already established in the West.” said Gabe. “I have been in the biologics space for over a decade and never have I seen such an incredible standalone product as NanoBone. I am humbled and honored to work with this team and utilize my extensive leadership experience in the biologics space to continue to take NanoBone to the next level!”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
425 E Saint Germain St., Suite 106
Saint Cloud, MN 56304
320-259-4321
info@artossinc.com

 

Artoss, Inc. Announces Hiring of William “Billy” Lapp as Director of Sales, East Coast


Press Release September 24, 2018

Artoss, Inc. is pleased to announce the hiring of William “Billy” Lapp as Director of Sales, East Coast. In this role, Billy will be responsible for growing the sales of NanoBone® Bone Graft in the region from Maine to South Carolina and west to Ohio and for identifying, training, and managing independent distributors in that region.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Billy has built a very successful sales career with small companies in the biotech industry and more recently in orthobiologics and tissue regeneration. He is uniquely trained to articulate the key advantages of NanoBone to orthopaedic and neurosurgeons. He has earned the respect of distributor partners and I know he’ll contribute to the continued growth of NanoBone sales in the US.”

“I’m excited to be joining Artoss as this stage in its development and look forward to expanding sales of NanoBone Bone Graft along the east coast.” said Billy. “It has been my dream to help build a great company delivering products that improve patients’ lives.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
425 E Saint Germain St., Suite 106
Saint Cloud, MN 56304
320-259-4321
info@artossinc.com

 

Artoss Announces Completion of $1 Million Funding Round


Press Release July 13, 2018

Artoss, Inc. is pleased to announce the successful completion of its recent funding round of Unsecured Convertible Notes. The round, which began in 2017 with a target of raising $500,000, was oversubscribed to twice that amount or a total of $1 million.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone® Bone Graft in orthopaedic surgery, said, “We have been overwhelmed by the interest shown in our second round of angel funding. We are especially grateful to those investors who participated in our 2016 funding round and chose to increase their investment in this round as well as to our new investors for their support of Artoss.”

Paul Byerley, Managing Director of Artoss, Inc. said, “We are very pleased with our commercial success to-date and appreciate the support of our investors. Surgeon feedback on the clinical performance of NanoBone SBX Putty and QDremains extremely positive. We look forward to expanding our distribution network to put our superior bone grafting solution in the hands of more surgeons.”.

Artoss, Inc. is using the proceeds of this funding to support the development of additional NanoBone Bone Graft products for the US market, for costs associated with regulatory requirements, and for commercialization activities.

For further information, please contact:

Artoss, Inc.
425 E Saint Germain St., Suite 106
Saint Cloud, MN 56304-0752
320-259-4321
info@artossinc.com

Artoss Announces NanoBone® QD Bone Graft


Press Release October 23, 2017

Artoss, Inc. is pleased to announce NanoBone QD Bone Graft.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “To extend the usability of NanoBone, we put the perfect handling of NanoBone SBX Putty in an applicator designed for QD – quick delivery. This easy-to-use device facilitates rapid implantation of our advanced bone graft in a controlled and precise manner. Artoss developed NanoBone QD to provide these benefits in a cost-effective delivery system.”

Walter Gerike, Managing Director of Artoss GmbH said, “Nanotechnology is the key technology for the 21st century and Artoss is harnessing this potential for orthopaedic surgery. With the launch of NanoBone SBX Putty in 2016, we created a product that combines Applied NanoBiology™ for bone repair with perfect handling for the surgeon. NanoBone QD takes the product one step further by making it easier for the surgeon to implant.” NanoBone synthetic bone graft products have been used in Europe and the US for more than ten years in approaching 400,000 clinical cases across all indications and has been available in the United States since 2015.

Artoss, Inc. is launching NanoBone QD at the North American Spine Society Meeting this week. Visit them at Booth 1562 to learn more.

For further information, please contact:

Artoss, Inc.15900 155th St. NE
Foley, MN 56329
320-355-4321

info@artossinc.com

Artoss, Inc. Announces Hiring of Ryan O’Neill as Director of Sales, Eastern Region


Press Release October 9, 2017

Artoss, Inc. is pleased to announce the hiring of Ryan O’Neill as Director of Sales, Eastern Region. In this role, Ryan will be responsible for introducing NanoBone® Bone Graft in the eastern half of the United States and for identifying, training, and managing independent distributors in that region.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Ryan has built a very successful career by introducing new biologic technologies pioneered by small innovative companies. He was a great asset when we worked together at ApaTech and I’m sure he’ll contribute to the continued growth of NanoBone sales in the US.”

“I’m excited to be educating orthopaedic and neurosurgeons about the concepts of Applied NanoBiology™ and the importance of nanostructured biomaterials to their practices”, said Ryan. “It’s good to be working with Paul and Jim again, bringing the next generation of advance bone grafting technology to patients.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in approaching 400,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com

Artoss, Inc. Announces DAPA Agreement for NanoBone® Bone Graft Products


Press Release September 15, 2017

Artoss, Inc. is pleased to announce that the full line of NanoBone Bone Graft products are now available through a Defense Acquisition Purchasing Agreement (DAPA) with the Prime Vendor, Owens & Minor. This will allow surgeons in any US Department of Defense healthcare facility to purchase NanoBone Bone Graft for use in surgery.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Nanotechnology is the key technology for the 21st century and NanoBone Bone Graft brings Applied NanoBiology™ to bone repair. We are proud to provide NanoBone to military surgeons that are providing the highest quality of care to our men and women in uniform.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in approaching 400,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com

Artoss Announces FDA Clearance to Market of NanoBone SBX Putty


Press Release November 8, 2016

Artoss, Inc. is pleased to announce that, on October 26, 2016, Artoss GmbH received notice from the U.S. Food & Drug Administration that NanoBone® SBX Putty has been cleared to market as 510(k) K161351.

Walter Gerike, Managing Director of Artoss GmbH said, “Nanotechnology is the key technology for the 21st century and Artoss is harnessing this potential for orthopaedic surgery. In NanoBone SBX Putty, we have a product that combines Applied NanoBiology™ for bone repair with perfect handling for the surgeon.” NanoBone synthetic bone graft products have been used in Europe for ten years in approaching 400,000 clinical cases across all indications.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, stated, “NanoBone technology has been in great demand by U.S. surgeons since we launched NanoBone Granules in 2015. NanoBone SBX Putty offers the same clinical performance in an easier to use presentation. We look forward to introducing this product in a variety of sizes to the U.S. market in the coming weeks.”

Contact:

Artoss, Inc.
15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com